Gilead’s current and future success lies in the hands of its antiviral franchise. That franchise, led by its hepatitis-C cures Sovaldi and Harvoni, accounted for roughly 60% of the company’s total product sales revenue in 2015. Analysts, however, are concerned that Harvoni’s sales may already have peaked. The company anticipates 230,000 U.S. patient starts in 2016, representing an 8% decline from 2015. Looking forward, Gilead plans to tackle another liver-attacking disease: nonalcoholic steatohepatitis, also known as nonalcoholic fatty liver disease, which affects 2% to 5% of Americans. On the deal-making front, the drugmaker acquired Nimbus Apollo, a subsidiary of Nimbus Therapeutics, in April. The deal was worth up to $1.2 billion and netted Gilead Nimbus Apollo’s lead experimental treatment for NASH, ACC inhibitor ND1-010976. Gilead also saw the recent approval of Descovy, a fixed-dose combination for the treatment of HIV. Descovy has similar efficacy to Viread — another Gilead HIV treatment — but at one tenth the dose. This drug is expected to give providers more flexibility in dosing for patients, as it’s often paired with other antiretrovirals in an HIV regimen.
Thank you for accessing MM+M.
Create your free account or log in to continue reading this premium content.